Connect with us

/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

UnitedHealthcare Helps Support Moms’ and Babies’ Health Before and After Delivery with New Bundled Payment Program for Maternity Care



Reading Time: 4 minutes

  • Bundled payment program has launched with care providers in New
    Jersey and Texas, with plans to expand to as many as 20 care provider
    groups by year-end 2019
  • Developed in collaboration with the U.S. Women’s Health
    Alliance, the program will be expanded to additional care provider
    groups that deliver quality, efficient care
  • Payment model builds upon existing maternity care program that
    has helped reduce the cesarean delivery rate for low-risk pregnancies
    across UnitedHealthcare’s employer-sponsored health plans to below
    national targets

MINNETONKA, Minn.–(BUSINESS WIRE)–UnitedHealthcare, a UnitedHealth Group (NYSE: UNH) company, has
introduced a new bundled payment program for maternity care to help
support the well-being of moms and babies before and after delivery by
closing gaps in care and encouraging healthy, full-term pregnancies.

The new bundled payment program for maternity care has launched with two
health care providers, Lifeline Medical Associates in New Jersey and
Privia Medical Group – Gulf Coast in Texas, to help encourage more
coordinated care and better health outcomes for expectant mothers
enrolled in UnitedHealthcare employer-sponsored health plans. By
year-end 2019, UnitedHealthcare will expand the bundled payment program
to as many as 20 care provider groups, including ones affiliated with
the U.S.
Women’s Health Alliance
, a national organization of leading health
care practices.

The payment model builds on the UnitedHealthcare Maternity program*,
which has helped women by contributing to fewer non-medically indicated
cesarean (C-section) deliveries, reduced both pre-delivery hospital
admissions and the average length of stay in the neonatal intensive care
unit (NICU), and decreased other delivery and newborn-related costs.2
The C-section rate for low-risk pregnancies among women enrolled in
UnitedHealthcare’s employer-sponsored health plans in 2018 was 18
percent,1 lower than the 23.9
percent target
set by the federal government.3

Approximately one-third
of babies nationwide are born via C-section, according to the Centers
for Disease Control and Prevention (CDC). Studies have shown that early,
non-medically indicated C-sections are linked to a higher risk of
complications, including infection, hemorrhage or blood clots, and
admission to the NICU.4

For a first-hand account of how UnitedHealthcare’s maternity resources
helped support a healthy, full-term delivery for a new mom, click

“These resources can help improve access to quality, coordinated care,
offering important support to women and families before, during and
after delivery,” said Janice Huckaby, M.D., who leads UnitedHealthcare’s
women’s health initiatives as a senior vice present and regional chief
medical officer. “Value-based care programs such as this help improve
clinical quality, patient safety and satisfaction, and care coordination
among physicians, with the goal of reducing costs.”

The bundled payment method reimburses a care provider or hospital for a
defined episode of care (EOC), such as prenatal, delivery and postpartum
services, under a single fee or payment. This is a shift away from the
common fee-for-service structure in which a care provider is paid for
each treatment, appointment or test, generating multiple claims within a
single, broader episode of care. Bundled payment methods reward care
providers for value over volume, helping align incentives and linking
reimbursement to the delivery of coordinated, efficient care.

“The collaboration to develop and launch this maternity episode of care
program marks an important next step in our journey to improve the
quality and affordability of care for women across America,” said Jack
Feltz, M.D, president of the U.S. Women’s Health Alliance. “This
transformative program helps give care providers the necessary resources
to make a difference in improving quality while decreasing costs.”

The UnitedHealthcare Healthy Pregnancy® mobile app** and Maternity
program provide expectant women with personalized content and 24/7 nurse
support. Nurses can coordinate care, help with the management of chronic
conditions, and connect pregnant women with behavioral health care teams
for emotional and mental health support. These resources are provided in
collaboration with Optum, UnitedHealth Group’s health services business.

Eligible people can download the app onto their iPhone® and
Android® devices, enabling expectant parents to:

  • connect with a registered nurse 24/7 for support and information;
  • monitor and track weight, set reminders to take vitamins and track
  • take a health assessment and discuss the results with a nurse;
  • receive customized weekly updates based on the baby’s gestational age;
  • search for information about pregnancy symptoms and concerns;
  • use a “kick counter” to track the baby’s movements; and
  • access health care cost estimates and plan benefit information.

Employers can offer these resources to their employees at no additional
cost as part of their benefit plan.**

The maternity care bundled payment program is part of UnitedHealthcare’s
ongoing commitment to value-based care. By the end of 2020, the company
expects to have $75 billion in care provider reimbursements tied to
value-based arrangements annually, which support the health of
UnitedHealthcare plan participants at no additional charge.

“Bringing together industry stakeholders with the collective vision to
work together to improve care quality and affordability will be crucial
for modernizing the nation’s health care system,” said Mark Cone, M.D.,
FACOG, market president, Privia Medical Group – Gulf Coast. “On behalf
of our doctors at Privia Medical Group, we are excited to be a part of
this collaborative effort.”

About UnitedHealthcare
is dedicated to helping people live healthier lives and making the
health system work better for everyone by simplifying the health care
experience, meeting consumer health and wellness needs, and sustaining
trusted relationships with care providers. In the United States,
UnitedHealthcare offers the full spectrum of health benefit programs for
individuals, employers, and Medicare and Medicaid beneficiaries, and
contracts directly with more than 1.2 million physicians and care
professionals, and 6,500 hospitals and other care facilities nationwide.
The company also provides health benefits and delivers care to people
through owned and operated health care facilities in South America.
UnitedHealthcare is one of the businesses of UnitedHealth Group (NYSE:
UNH), a diversified health care company. For more information, visit
UnitedHealthcare at
or follow @UHC on Twitter.

All trademarks are property of their respective owners.

*The information provided under this program is for general
informational purposes only and is not intended to be nor should be
construed as medical and/or nutritional advice. Participants should
consult an appropriate health care professional to determine what may be
right for them. Employers are responsible for ensuring that any wellness
programs they offer to their employees comply with applicable state
and/or federal law, including, but not limited to, GINA, ADA and HIPAA
wellness regulations, which in many circumstances contain maximum
incentive threshold limits for all wellness programs combined that are
generally limited to 30 percent of the cost of self-only coverage of the
lowest-cost plan and prohibitions on incentives to dependent children,
as well as obligations for employers to provide certain notices to their
employees. Employers should discuss these issues with their own legal

**The UnitedHealthcare Healthy Pregnancy application is available only
to eligible participants enrolled in certain employer-sponsored plans.
Application registration is required.

1UnitedHealthcare Economics Women’s Health Outcomes Analysis,
2Optum Healthcare Economics Maternity Program
Analytics Study, 2018
3 Office of Disease Prevention and
Health Promotion
The Journal of Maternal-Fetal & Neonatal Medicine, 2016

here to subscribe to Mobile Alerts for UnitedHealth Group


Will Shanley
(714) 204-8005
[email protected]

Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493


Innocan Pharma Announces Study Findings that LPT-CBD maintains its prolonged release in Rabbits




HERZLIYA, Israel and CALGARY, AB, Feb. 26, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce the latest findings from the Company’s pharmacokinetic study of its LPT-CBD platform in rabbits.

The fundamentals of LPT-CBD lay in its ability to slowly release CBD into the blood stream. Studies conducted in various animal models including mice, dogs, goats, and sheep showed long pharmacokinetics of CBD that persisted up to several weeks. In the Company’s latest study conducted on rabbits, the results showed additional supportive data for the long exposure of CBD obtained following a single subcutaneous LPT-CBD injection.   

The Company is encouraged by these study results as they confirm the approach the Company is taking with its LPT platform. The results from studies of several organisms injected with the Company’s liposomal CBD –have consistently demonstrated that a detectable CBD level could be maintained for weeks following one injection. The Company will continue with human trials in the near future.

Pharmacokinetics (PK) is an important tool that helps evaluate the bioavailability and exposure level of a specific drug. Parameters such as maximal blood drug concentration (cMax), time to reach cMax (Tmax) and half-life of the drug are calculated based on data collected from blood analysis of the drug across a determined time. The collected PK parameters along with other tests help to define the required dose of a drug to achieve a maximal therapeutic effect. In the study conducted on rabbits, the animals were collected for blood analysis of the drug for up to 11 days. As expected, the animals presented a persistent CBD concentration in their blood that maintained through the entire testing period. This correlates to PK results obtained from other species, supporting the long CBD exposure and the necessity of only a single LPT-CBD injection to obtain a long and wide therapeutic window for CBD.   

About Innocan Pharma:

Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD-loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales.

Contact Information:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1 5162104025


Caution Regarding Forward-Looking Information

Certain information set forth in this news release, including, without limitation, the Company’s plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. . The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan’s public reports and filings which are available under Innocan’s profile at

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.


Cision View original content:

Continue Reading


Schwazze Appoints Forrest Hoffmaster as Interim Chief Executive Officer




DENVER, Feb. 23, 2024 /PRNewswire/ — Medicine Man Technologies, Inc., operating as Schwazze, (OTCQX: SHWZ) (NEO: SHWZ) (“Schwazze” or the “Company”), today announced that Forrest Hoffmaster, the Company’s Chief Financial Officer, has been appointed to the additional role of interim Chief Executive Officer (“CEO”). This follows Nirup Krishnamurthy’s resignation as CEO and as a member of the Board of Directors (“Board”), effective February 20, 2024, due to personal reasons.

Mr. Hoffmaster, who joined the Company in January 2023, brings over 30 years of executive experience in finance and operations for both public and private companies. Prior to Schwazze, Mr. Hoffmaster served as CEO of New Seasons Market, a specialty gourmet food retailer, where he navigated the company through one of the most disruptive periods in the retail grocery industry. Under his leadership, Mr. Hoffmaster implemented a focused growth and cost optimization program, enabling the company to grow EBITDA by over 30% in two years. Prior to New Seasons Market, Forrest held leadership positions with other leading grocers including Whole Foods Market and H-E-B.

“Forrest is well-positioned to seamlessly step in and lead the Company’s day-to-day operations as we conduct our search for a permanent successor,” said Justin Dye, Chairman of the Board. “With Forrest’s proven track record and deep retail expertise, we plan to continue leveraging our operating playbook to drive strong Adjusted EBITDA margins and consistent cash flow generation. On behalf of the Board, I’d like to wish Nirup the best in his future endeavors.”

About Schwazze

Schwazze (OTCQX: SHWZ) (NEO: SHWZ) is building a premier vertically integrated regional cannabis company with assets in Colorado and New Mexico and will continue to take its operating system to other states where it can develop a differentiated regional leadership position. Schwazze is the parent company of a portfolio of leading cannabis businesses and brands spanning seed to sale.

Schwazze is anchored by a high-performance culture that combines customer-centric thinking and data science to test, measure, and drive decisions and outcomes. The Company’s leadership team has deep expertise in retailing, wholesaling, and building consumer brands at Fortune 500 companies as well as in the cannabis sector.

Medicine Man Technologies, Inc. was Schwazze’s former operating trade name. The corporate entity continues to be named Medicine Man Technologies, Inc. Schwazze derives its name from the pruning technique of a cannabis plant to enhance plant structure and promote healthy growth. To learn more about Schwazze, visit

Forward-Looking Statements

This press release contains “forward-looking statements.” Such statements may be preceded by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intends,” “plans,” “strategy,” “prospects,” “anticipate,” “believe,” “approximately,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other words of similar meaning in connection with a discussion of future events or future operating or financial performance, although the absence of these words does not necessarily mean that a statement is not forward-looking. Forward-looking statements are not guarantees of future events or performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified. Consequently, actual events and results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) regulatory limitations on our products and services and the uncertainty in the application of federal, state, and local laws to our business, and any changes in such laws; (ii) our ability to manufacture our products and product candidates on a commercial scale on our own or in collaboration with third parties; (iii) our ability to identify, consummate, and integrate anticipated acquisitions; (iv) general industry and economic conditions; (v) our ability to access adequate capital upon terms and conditions that are acceptable to us; (vi) our ability to pay interest and principal on outstanding debt when due; (vii) volatility in credit and market conditions; (viii) the loss of one or more key executives or other key employees; and (ix) other risks and uncertainties related to the cannabis market and our business strategy. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise except as required by law.

Investor Relations Contact
Sean Mansouri, CFA or Aaron D’Souza
Elevate IR
(720) 330-2829
[email protected] 

View original content:

Continue Reading


Hemp, Inc. Reports: Hemp-Based Foods Market Set to Reach $8.36 Billion by 2028



Continue Reading

Trending on Grassnews Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with

Contact us: [email protected]

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania